Form 483

Niagara Pharmaceuticals, Inc Form 483, 2020-02-07

FDA issued a Form 483 to Niagara Pharmaceuticals, Inc on 2020-02-07 with 2 public-safe observations.

483· Form 483 issuedHuman Drugs2 observations

Niagara Pharmaceuticals, Inc · Dundas, Canada · Issued February 7, 2020

Overview

  • 2 public-safe observations are available for this inspection.
  • 2 structured CFR citations are represented.
  • 1 investigator is tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

7 Feb 2020
21 CFR 211.192

Investigations of discrepancies, failures

Cited by Jay T Wong

7 Feb 2020
21 CFR 211.63

Equipment Design, Size and Location

Cited by Jay T Wong

Inspected site

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.192Cited across public-safe Form 483 observations1x
21 CFR 211.63Cited across public-safe Form 483 observations1x

Full 483 report

Get the verbatim text of all 2 observations

The full inspection record, as Atlas holds it, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere